How Investors Are Reacting To Ionis Pharmaceuticals (IONS) Raising Revenue Guidance and Narrowing Losses

• Ionis Pharmaceuticals reported third-quarter 2025 results, with revenue rising to US$156.72 million and net loss narrowing to US$128.61 million compared to the prior year; the company also raised its full-year revenue guidance to a range of US$875 million to US$900 million, above previous expectations.
• Management signaled increased investment in commercial preparations for upcoming therapies, highlighting confidence in the company's late-stage pipeline and anticipated product launches next year.
• We'll assess how Ionis Pharmaceuticals' improved outlook, driven by strong quarterly revenue and guidance, impacts its long-term investment case.

We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Ionis Pharmaceuticals Investment Narrative Recap

To be a shareholder in Ionis Pharmaceuticals, you need to believe in the company’s ability to successfully launch and commercialize its late-stage therapies, especially as it shifts from an R&D-focused model to a fully integrated commercial business. The recent news of higher-than-expected revenue and increased guidance adds near-term confidence, but the key catalyst remains regulatory progress and FDA approvals, any delays or setbacks to these launches remain the largest immediate risk. The overall impact of this earnings beat on near-term pipeline risks appears modest, with major catalysts unchanged.

Among the latest developments, Ionis revised its full-year 2025 revenue guidance upward, to US$875 million to US$900 million, on the back of strong quarterly sales and anticipated product launches. This increased guidance follows the company’s announcement of positive Phase III data for late-stage assets like olezarsen and zilganersen, reinforcing management’s optimism for upcoming regulatory milestones, which are still the most important levers for value creation in the coming year.

By contrast, investors should remain aware that execution risks on upcoming launches and pricing negotiations could...

Read the full narrative on Ionis Pharmaceuticals (it's free!)

Ionis Pharmaceuticals' narrative projects $1.5 billion in revenue and $241.3 million in earnings by 2028. This requires 16.7% yearly revenue growth and a $509.5 million increase in earnings from the current -$268.2 million.

Uncover how Ionis Pharmaceuticals' forecasts yield a $82.15 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates for Ionis Pharmaceuticals range from US$36.19 to US$225.54 per share. With approvals for key therapies still pending, your outlook may depend on how you weigh regulatory and market access risks in the months ahead.

Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Build Your Own Ionis Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com